We cannot wait welcome our newest class of residents Moffitt Cancer Center! Congratulations to Emily Keit MD, Vaseem Khatri MD, and Justyn Nakashima, DO DO! #RadOnc #MatchDay2021 Jessica Frakes Stephen Rosenberg, MD

Is SRS WITH tucatinib for brain mets safe? Based on this study, Yes. · 135 lesions SRS · 4% symptomatic radiation necrosis rdcu.be/dihvn

Thanks Dr. Ahmed Michael Vogelbaum & Moffitt Cancer Center colleagues important addition to literature 1 yr LC 94% 44% SRS sessions concurrent, 56% delivered sequentially prior to tucatinib initiation Tucatinib is a HER2-targeted TKI Study particularly relevant w/common use HER2-CLIMB regimen

Patients can benefit from SBRT / PBT over TACE in HCC (ineligible for upfront surgery/transplant) ! 🚨 Local Control HR 0.16 (0.08, 0.34) 🚨 💥 PFS HR 0.37 (0.23, 0.60) 💥 OS RR 0.79 (0.51, 1.22) Toxicity RR 0.86 (0.31, 2.37)

HOT OFF THE PRESS! Neoadjuvant PAE prior to prostate radiation therapy: A single institution experience on the durability of clinical urinary improvement after radiation - ctro.science/article/S2405-… Moffitt Cancer Center MoffittRadOnc Kosj Yamoah MD, PhD G. Daniel Grass MD, PhD Vaseem Khatri Clinical & Translational Radiation Oncology

post PAE IPSS/QoL improvement persists post-RT